Nexalin Therapy as a Viable Adjunctive Treatment for Substance Use Disorders
Not Applicable
Active, not recruiting
- Conditions
- AnxietySubstance AbuseDepressionInsomnia
- Registration Number
- NCT03540745
- Lead Sponsor
- University of Arizona
- Brief Summary
The purpose of this research study is to determine whether Nexalin Trans-cranial Electrical Stimulation (TES) is a viable adjunctive treatment of substance use treatments.
- Detailed Description
A Randomized Controlled Trial with block randomization. Inpatient subjects actively seeking substance abuse treatment at the Carrier Clinic who are diagnosed with a substance use disorder, including alcohol use disorder, tobacco use disorder, polysubstance use disorder, or other substance use disorder.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 14
Inclusion Criteria
- Be able to provide informed consent, assessed by the study clinician
- Be able to speak, read and write fluently in English, assessed by the study clinician
- Be committed to completion of the study. The subject will need to attest to availability for 10 to 15 treatments over a 5 to 8 day period for the treatment protocol.
- Be adults over age 18 and under age 65
- Be actively receiving substance use treatment for a substance use disorder
Exclusion Criteria
- Pregnant or at risk of becoming pregnant
- Individual has a condition the Investigator believes would interfere with his or her ability to provide informed consent, comply with the study protocol, might confound the interpretation of the study results, or put the person at undue risk
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Treatment response 5-8 Days Reduction in depressive symptoms as a result of Nexalin vs Sham
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Carrier Clinic
🇺🇸Belle Mead, New Jersey, United States
Carrier Clinic🇺🇸Belle Mead, New Jersey, United States